Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Niesvizky · SciRah

Researcher profile · Semantic Scholar

R. Niesvizky

Share profile

R. Niesvizky — researcher profile on SciRah

h-index: 64
Works: 439
Citations: 19K

Most-cited papers

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
A. Lesokhin, M. Tomasson, B. Arnulf, N. Bahlis +25 more
2023Nature Medicine613 citations Open access
Semantic Scholar
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
N. Raje, E. Anaissie, Shaji K. Kumar, S. Lonial +32 more
2022The Lancet Haematology168 citations
Semantic Scholar
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Sheri Skerget, Daniel A. Peñaherrera, A. Chari, Sundar Jagannath +124 more
2024Nature Genetics82 citations Open access
Semantic Scholar
Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
N. Bahlis, M. Tomasson, M. Mohty, R. Niesvizky +18 more
2022Blood52 citations Open access
Semantic Scholar
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
M. Hultcrantz, J. Richter, C. Rosenbaum, D. Patel +26 more
2020Blood Cancer Discovery52 citations Open access
Semantic Scholar
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
A. Nooka, A. Lesokhin, M. Mohty, R. Niesvizky +15 more
2023Journal of Clinical Oncology39 citations
Semantic Scholar
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
M. Hultcrantz, J. Richter, C. Rosenbaum, D. Patel +24 more
2020medRxiv36 citations Open access
Semantic Scholar
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
Mateo Mejia Saldarriaga, D. Pan, Caitlin Unkenholz, Tarek H. Mouhieddine +21 more
2024Blood Advances34 citations Open access
Semantic Scholar
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
Olivia Perez de Acha, Lauren T. Reiman, D. Jayabalan, Z. Walker +10 more
2023Blood Advances34 citations Open access
Semantic Scholar
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
T. Facon, R. Niesvizky, M. Mateos, D. Siegel +14 more
2020Blood Advances32 citations Open access
Semantic Scholar
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Sarah Goldman-Mazur, A. Jurczyszyn, J. Castillo, A. Waszczuk-Gajda +39 more
2020American journal of hematology/oncology27 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
M. Tomasson, S. Iida, R. Niesvizky, M. Mohty +10 more
2023Blood26 citations Open access
Semantic Scholar
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
J. Shah, Saad Usmani, E. Stadtmauer, R. Rifkin +6 more
2019Clinical Lymphoma, Myeloma & Leukemia25 citations
Semantic Scholar
Hematogenous extramedullary relapse in multiple myeloma ‐ a multicenter retrospective study in 127 patients
I. Avivi, Y. Cohen, A. Suska, T. Shragai +18 more
2019American journal of hematology/oncology25 citations Open access
Semantic Scholar
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
N. Puig, M. Hernandez, L. Rosiñol, E. González +34 more
2021Blood Cancer Journal23 citations Open access
Semantic Scholar
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
A. Krishnan, K. Patel, P. Hari, S. Jagannath +7 more
2019Blood23 citations Open access
Semantic Scholar
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic
M. Shah, M. F. Emlen, T. Shore, S. Mayer +15 more
2020Ca20 citations Open access
Semantic Scholar
A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.
A. Krishnan, K. Patel, P. Hari, S. Jagannath +6 more
202019 citations
Semantic Scholar
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
A. Gomez-Arteaga, T. Mark, Danielle Guarneri, P. Christos +11 more
2019Bone Marrow Transplantation19 citations
Semantic Scholar
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
M. Mohty, M. Tomasson, B. Arnulf, N. Bahlis +16 more
2023Journal of Clinical Oncology18 citations Open access
Semantic Scholar
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
M. Dimopoulos, R. Niesvizky, K. Weisel, D. Siegel +6 more
2020Blood Cancer Journal17 citations Open access
Semantic Scholar
Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
A. Lesokhin, B. Arnulf, R. Niesvizky, M. Mohty +12 more
2022Journal of Clinical Oncology16 citations
Semantic Scholar
Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study
Sheri Skerget, Daniel A. Peñaherrera, A. Chari, S. Jagannath +54 more
2021medRxiv16 citations Open access
Semantic Scholar
PS1071 PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES
N. Shah, A. Krishnan, J. Burke, J. Melear +13 more
2019HemaSphere16 citations Open access
Semantic Scholar
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide
Liang Zhou, Xian-Gao Huang, R. Niesvizky, Zhongjian Pu +1 more
2021Journal of Pharmacology and Experimental Therapeutics14 citations Open access
Semantic Scholar
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
Mateo Mejia Saldarriaga, W. Darwiche, D. Jayabalan, J. Monge +4 more
2022Frontiers in Oncology13 citations Open access
Semantic Scholar
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
T. Mark, Peter A. Forsberg, A. Rossi, R. Pearse +7 more
2019Blood Advances13 citations Open access
Semantic Scholar
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
A. Chari, R. Cornell, C. Gasparetto, C. Karanes +13 more
2020Hematological Oncology12 citations Open access
Semantic Scholar
Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial
Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga +13 more
2023Blood9 citations Open access
Semantic Scholar
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements
Robert J. Kimmerling, Mark M. Stevens, S. Olcum, A. Minnah +18 more
2022Communications Biology9 citations Open access
Semantic Scholar
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
N. Biran, B. Dhakal, S. Lentzsch, D. Siegel +16 more
2021eJHaem8 citations Open access
Semantic Scholar
Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma.
Shaji K. Kumar, A. Fu, R. Niesvizky, S. Jagannath +2 more
2021Blood Advances8 citations Open access
Semantic Scholar
Daratumumab in Patients with Multiple Myeloma and Renal Impairment - Real-World Data from a Single-Center Institution
J. Monge, Robin S. Solomon, Kari Flicker, D. Jayabalan +11 more
2019Blood8 citations
Semantic Scholar
Angioimmunoblastic T‐cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia
Mateo Mejia Saldarriaga, Mohammad Alhomoud, G. Roboz, J. Allan +5 more
2023American journal of hematology/oncology7 citations
Semantic Scholar
SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)
J. Hoffman, B. Lipe, J. Melear, M. Liedtke +9 more
2021Blood7 citations Open access
Semantic Scholar
Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function
Liang Zhou, Wenjun Yu, D. Jayabalan, R. Niesvizky +3 more
2020Frontiers in Cell and Developmental Biology7 citations Open access
Semantic Scholar
Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use
Danny Luan, P. Christos, M. Ancharski, Danielle Guarneri +11 more
20207 citations Open access
Semantic Scholar
Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial.
Darrell White, B. Lipe, Mercedes Gironella-Mesa, R. Niesvizky +15 more
2025Journal of Clinical Oncology5 citations
Semantic Scholar
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Sarah Goldman-Mazur, A. Jurczyszyn, J. Castillo, A. Waszczuk-Gajda +39 more
2020Leukemia and Lymphoma5 citations Open access
Semantic Scholar
High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies
A. Keller, Olivia Perez De Acha, Lauren T. Reiman, Z. Walker +8 more
2022Blood4 citations Open access
Semantic Scholar
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
N. Shah, A. Krishnan, Nina Shah, John M. Burke +15 more
2019Blood4 citations Open access
Semantic Scholar
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.
Hans C. Lee, W. Plattel, Simon J. Harrison, Doug Sborov +15 more
2026Blood3 citations Open access
Semantic Scholar
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies
Mark M. Stevens, Robert J. Kimmerling, S. Olcum, Madeleine Vacha +19 more
2024JCO Precision Oncology3 citations Open access
Semantic Scholar
Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy.
J. Velez-Hernandez, Mateo Mejia Saldarriaga, M. Bustoros, R. Pearse +2 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption
R. Niesvizky, B. Arnulf, M. Mohty, A. Nooka +8 more
2023Blood3 citations Open access
Semantic Scholar
P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
S. Manier, A. Lesokhin, M. Mohty, R. Niesvizky +15 more
2023HemaSphere3 citations Open access
Semantic Scholar
Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database.
Mateo Mejia Saldarriaga, D. Jayabalan, Aubrie Sowa, J. Monge +5 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
P-320 Iberdomide (IBER) plus dexamethasone (DEX) in patients with relapsed/refractory multiple myeloma (RRMM): a safety analysis from the CC-220-MM-001 trial
N. V. van de Donk, Darrell White, B. Lipe, Abdullah Khan +15 more
2023Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis
C. Rosenbaum, Umut Özbek, L. Sanchez, J. Lagdameo +6 more
2022Blood Advances3 citations Open access
Semantic Scholar
Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution
J. Monge, Kari Flicker, Danielle Guarneri, Robin S. Solomon +17 more
2019Blood3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Jayabalan×13
Invite
D. Jayabalan — researcher profile on SciRah
R. Pearse×11
Invite
R. Pearse — researcher profile on SciRah
A. Lesokhin×10
Invite
A. Lesokhin — researcher profile on SciRah
C. Rosenbaum×10
Invite
C. Rosenbaum — researcher profile on SciRah

×9

Invite

A. Rossi — researcher profile on SciRah

Invite

N. Bahlis — researcher profile on SciRah

Invite

N. Raje — researcher profile on SciRah

Invite

E. Leip — researcher profile on SciRah

Invite

A. Viqueira — researcher profile on SciRah

Invite

A. Nooka — researcher profile on SciRah

Invite

M. Mohty — researcher profile on SciRah

Invite

B. Arnulf — researcher profile on SciRah